Amoun Pharmaceutical Company S.A.E.

[ Editor's Note: A version of this article originally appeared in Scrip . For more insight on the the B+L spin-off from the perspective of the over-the-counter industry, see Informa's HBW Insig

Following several years of preparation and build-up of anticipation, the Bausch Health Companies Inc. split went into effect on 10 May, with the closing of a $630m initial public offering for Bausc

Bausch Health Companies Inc. CEO Joseph Papa told investors on 4 May that the planned separation into two companies is making progress and either a spinout or initial public offering of the Bausch +

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche Agrees To Pay $1.8bn For GenMark